In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

EU exports to the US reached $605.8 billion in 2024, according to the US Census Bureau. Pharmaceutical companies are ...

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...